natgillin/translations-raw huggingface dataset:
Very commonly reported side effects (at least 1 in every 10 patients): pain, swelling and redness or skin damage at site of injection, hair loss, dizziness, changes in appetite, stomach or abdominal pains, diarrhoea, nausea (feeling sick), viral infection, depression, emotional lability, insomnia, anxiety, sore throat and painful swallowing, fatigue, chills/rigors, fever, flu-like reaction, feeling of general discomfort, headaches, weight loss, vomiting, irritability, weakness, mood swings, coughing (sometimes severe), shortness of breath, itching, dry skin, rash, sudden and severe muscle pain, joint pain, musculoskeletal pain, changes in laboratory blood values including decreased white blood cell count.
Zelo pogosto opisani neželeni učinki (pri najmanj 1 na vsakih 10 bolnikov): bolečine, otekanje in pordelost ali poškodbe kože na mestu injiciranja, izpadanje las, omotica, sprememba teka, želodčne ali trebušne bolečine, driska, slabost (siljenje na bruhanje), virusne okužbe, depresija, čustvena nestabilnost, nespečnost, tesnoba, vnetje žrela in bolečine pri požiranju, utrujenost, mrzlica/ tresavica, zvišana telesna temperatura, gripi podobno stanje, splošni občutek neugodja, glavoboli, hujšanje, bruhanje, razdražljivost, šibkost, nihanje razpoloženja, kašelj (včasih hud), težko dihanje, srbenje, suha koža, izpuščaj, nenadne in hude mišične bolečine, sklepne bolečine, mišičnoskeletne bolečine, spremembe izvidov laboratorijskih krvnih preiskav vključno z zmanjšanim številom belih krvničk.
Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients): thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, problem with your tear ducts, conjunctivitis (“pink eye”), agitation, sleepiness, sleepwalking, problem with behaviour, nervousness, stuffy or runny nose, sneezing, rapid breathing, pale or reddened skin, bruising, fingers and toes very sensitive to cold, problem with skin or nails, psoriasis (new or worsened), increased sweating, increased need to pass urine, fine shaking movements, decreased sensitivity to touch, arthritis.  Uncommonly reported side effects (at least 1 in every 1000 patients, but less than 1 in every 100 patients): bacterial infection and feeling of pins and needles.
Pogosto opisani neželeni učinki (pri najmanj 1 na vsakih 100 bolnikov, vendar manj kot 1 na vsakih 10 bolnikov): žeja, dehidracija, zvišan krvni tlak, migrene, otekle bezgavke, pordelost, težave z menstruacijo, zmanjšana spolna sla, vaginalne težave, bolečine v dojkah, bolečine v modih, težave z žlezo ščitnico, pordele dlesni, suha usta, pordela ali vneta usta ali jezik, zobobol ali zobne bolezni, herpes simpleks (vročinske razjede), sprememba okusa, želodčne težave, dispepsija (zgaga), zaprtje, povečanje jeter (jetrne težave, včasih hude), vodeno blato, močenje postelje pri otrocih, vnetje sinusov, bronhitis, očesne bolečine, težave s solznimi kanalčki, konjunktivitis (“ rdeče oko ”), vznemirjenost, zaspanost, hoja v spanju, vedenjske težave, živčnost, zamašen nos ali izcedek iz nosa, kihanje, hitro dihanje, bleda ali pordela koža, podplutbe, velika občutljivost prstov na rokah in nogah na mraz, težave s kožo ali nohti, psoriaza (novonastala ali poslabšanje obstoječe), povečano potenje, večja potreba po odvajanju urina, drobni tresoči gibi, zmanjšana občutljivost za dotik, artritis.
Rarely reported side effects (at least 1 in every 10,000 patients, but less than 1 in every 1,000 patients): pneumonia.
Redko opisani neželeni učinki (pri najmanj 1 na vsakih 10. 000 bolnikov, vendar manj kot 1 na vsakih 1. 000 bolnikov): pljučnica.
Very rarely reported side effects (less than 1 in every 10,000 patients): low blood pressure, puffy face, diabetes, leg cramps, back pain, kidney problems, nerve damage, bleeding gums, aplastic anaemia.
Zelo redko opisani neželeni učinki (pri manj kot 1 na vsakih 10. 000 bolnikov): nizek krvni tlak, zabuhel obraz, sladkorna bolezen, krči v nogah, bolečine v hrbtu, težave z ledvicami, poškodbe živcev, krvavitev iz dlesni, aplastična anemija.
Periodontal (affecting gums) and dental disorders, altered mental status, loss of consciousness, acute hypersensitivity reactions including urticaria (hives), angioedema (swelling of the hands, feet, ankles, face, lips, mouth, or throat which may cause difficulty in swallowing or breathing), bronchoconstriction and anaphylaxis (a severe, whole -body allergic reaction) have been reported, but their frequency is unknown.
Poročali so tudi o periodontalni bolezni (prizadetost dlesni), zobnih boleznih, spremenjenem duševnem stanju, izgubi zavesti ter akutnih preobčutljivostnih reakcijah, vključno z urtikarijo (koprivnica), angioedemom (otekanje dlani, stopal, gležnjev, obraza, ustnic, ust ali žrela, ki lahko povzroči težave pri požiranju ali dihanju), bronhokonstrikcijo in anafilaksijo (huda alergijska reakcija po vsem telesu), vendar njihova pogostnost ni znana.
Additionally, Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord), thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement) have been reported with IntronA use.
363 Poleg tega so pri uporabi zdravila IntronA poročali tudi o pojavu sindroma Vogt- Koyanagi- Harada (avtoimunska vnetna bolezen, ki prizadene oči, kožo in ušesne membrane ter ovojnice možgan in hrbtenjače), misli kako ogroziti življenje drugih, manije (čezmerno ali nesmiselno navdušenje), bipolarne motnje (motnja razpoloženja, za katero je značilno izmenjevanje obdobij žalostnega razpoloženja z obdobji navdušenosti).
 349 Other side effects not listed above may also occur in some patients.
Pri nekaterih bolnikih se lahko pojavijo tudi drugi neželeni učinki, ki niso navedeni zgoraj.
HOW TO STORE INTRONA
SHRANJEVANJE ZDRAVILA INTRONA
Do not use IntronA after the expiry date which is stated on the package.
Zdravila IntronA ne smete uporabljajti po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Do not use IntronA if you notice changes in the appearance of IntronA.
Ne uporabljajte zdravila IntronA, če opazite spremembe videza zdravila IntronA.
- The active substance is recombinant interferon alfa-2b, 1 million IU/ml.
- Zdravilna učinkovina je rekombinantni interferon alfa- 2b, 1 milijon i. e. / ml.
- The other ingredients are glycine, disodium phosphate anhydrous, sodium dihydrogen phosphate
- Pomožne snovi so glicin, brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat
monohydrate, and human albumin solution.
in raztopina humanega albumina.
- Solvent: water for injections 1 ml/ampoule
- Vehikel: voda za injekcije 1 ml/ ampula.
IntronA is presented as a powder and solvent for solution for injection or infusion.
IntronA je na voljo kot prašek in vehikel za raztopino za injiciranje ali infundiranje.
The white to cream coloured powder is contained in a 2 ml glass vial, and the clear and colourless solvent is presented in a 2 ml glass ampoule with 1 injection syringe, 2 injection needles and 1 cleansing swab.
Prašek bele do krem barve je v 2 ml stekleni viali, bister in brezbarven vehikel pa v 2 ml stekleni ampuli z 1 injekcijsko brizgo, 2 injekcijskima iglama in 1 čistilnim tamponom.
Pack size of 1 or 12.
Velikost pakiranja po 1 ali 12.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
364 Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Slovenská republika Strakova 5 SK-811 01 Bratislava Tel: + 421 (2) 5920 2712
365 Slovenská republika Ísland Strakova 5 Hörgatún 2 SK- 811 01 Bratislava IS- 210 Garðabær Tel: + 421 (2) 5920 2712 Sími: + 354 535 70 00
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.europa.eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /.
 352 HOW TO SELF INJECT INTRONA
366 KAKO SI LAHKO SAMI INJICIRATE ZDRAVILO INTRONA
Your doctor or his/her assistant will instruct you how to self- inject IntronA.
Zdravnik ali sestra vas bosta poučila, kako naj si sami injicirate zdravilo IntronA.
Preparation Collect necessary items before you begin:
Priprava Preden začnete, si pripravite vse potrebne pripomočke:
- a vial of IntronA powder for injection;
- vialo zdravila IntronA prašek za injiciranje;
- an ampoule of solvent for IntronA (water for injections 1 ml);
- ampulo topila za zdravilo IntronA (voda za injiciranje 1 ml);
- a 2 ml syringe;
- 2 ml brizgo;
- a long needle (for example 0.8 x 40 mm [21 gauge 1.5 inch]) to be used to add water for
dolgo iglo (na primer 0, 8  40 mm), ki jo boste uporabili za dodajanje vode za injekcije v vialo
injections to the IntronA powder vial;
-
- a short needle (for example 0.3 x 13 mm [30 gauge 0.5 inch]) for the subcutaneous injection;
s praškom zdravila IntronA; kratko iglo (na primer 0, 3  13 mm) za subkutano injiciranje;
- a cleansing swab.
- čistilni tampon.
Reconstituting IntronA powder for injection Remove the protective cap from the IntronA vial.
Rekonstitucija zdravila IntronA prašek za injiciranje Snemite zaščitno kapico z viale zdravila IntronA.
To prepare the IntronA solution insert the needle through the rubber top of the IntronA vial and gently place the needle tip against the glass wall of the vial without touching the cleaned top of the vial with your hands.
Za pripravo raztopine zdravila IntronA vbodite iglo skozi gumijasti vrh viale z zdravilom IntronA in previdno naslonite vrh igle na stekleno steno viale, ne da bi se pri tem z rokami dotaknili očiščenega vrha viale.
Do not aim the stream at the white powder at the bottom of the vial.
Curka ne usmerjajte v beli prašek na dnu viale.
To dissolve the white contents, swirl the IntronA vial with a gentle rotary motion leaving the syringe needle in the vial, until the contents are completely dissolved.
Da se bo bela vsebina viale zdravila IntronA raztopila, le- to nežno obračajte, pri čemer naj igla z brizgo ostane v viali, dokler se vsebina viale popolnoma ne raztopi.
Measuring the dose of IntronA from the reconstituted powder for injection Turn the vial and the syringe upside down in one hand.
Merjenje odmerka zdravila IntronA iz rekonstituranega praška za injiciranje Obrnite vialo in brizgo narobe in ju držite v eni roki.
Be sure the tip of needle is in the IntronA reconstituted solution.
Pazite, da bo vrh igle potopljen v rekonstituirani raztopini zdravila IntronA, z drugo roko pa boste premikali bat brizge.
Your other hand will be free to move the plunger.
Počasi povlecite bat nazaj, da posesate ustrezen odmerek zdravila, kot ga je predpisal vaš zdravnik, v brizgo.
Pull back on the plunger slowly to draw the correct dose as prescribed by your doctor into the syringe.
Brizgo z iglo v viali držite obrnjeno navzgor.
 353 Injecting the solution Select the injection site.
Injiciranje raztopine Izberite si mesto, kamor boste injicirali zdravilo.
The best sites for injection are tissues with a layer of fat between skin and muscle: thigh, outer surface of the upper arm (you may need the assistance of another person to use this site), abdomen (except the navel or waistline).
Najboljša mesta za injiciranje so tkiva s plastjo maščevja med kožo in mišicami: stegno, zunanja površina nadlahti (tu boste morda potrebovali pomoč
Insert the needle into the pinched skin at an angle of 45° to 90°.
Vbodite iglo v kožno gubo pod kotom 45 do 90.
INFORMATION FOR THE USER
368 NAVODILO ZA UPORABO
IntronA 3 million IU/ml powder and solvent for solution for injection or infusion Interferon alfa-2b
IntronA 3 milijoni i. e. / ml prašek in vehikel za raztopino za injiciranje ali infundiranje interferon alfa- 2b
 356 Using IntronA with food and drink While being treated with IntronA, your doctor may want you to drink extra fluids to help prevent low blood pressure.
370 Uporaba zdravila IntronA skupaj s hrano in pijačo Medtem, ko prejemate zdravilo IntronA vam bo vaš zdravnik lahko naročil, naj pijete več tekočine, da bi preprečili nizek krvni tlak.
 357 If you are injecting IntronA yourself, please be sure that the dose that has been prescribed for you is clearly provided with the package of medicine you receive.
371 Če si zdravilo IntronA injicirate sami, pazite, da bo predpisani odmerek jasno napisan na pakiranju zdravila, ki ga jemljete.
The infusion must be prepared immediately prior to use.
Infuzijska raztopina mora biti pripravljena tik pred uporabo.
 358 Use IntronA exactly as prescribed by your doctor.
372 Pri uporabi zdravila IntronA natančno upoštevajte zdravnikova navodila.
confusion, difficulty remaining alert, numbness or tingling sensation or pain in hands or feet; seizure (convulsions); trouble sleeping, thinking or concentrating; altered mental state; suicidal thoughts, suicide attempt, changed behaviour or aggressive behaviour (sometimes directed against others), hallucinations; severe stomach pain; black or tar like stools; blood in stool or urine, severe nosebleed; waxy pallor, high sugar level in blood, fever or chills beginning after a few weeks of treatment, lower back or side pain, difficult urination, problems with your eyes or your eyesight or hearing, loss of hearing, severe or painful reddening or sores on your skin or mucous membrane.
Če se pojavi kateri od naslednjih neželenih učinkov, se nemudoma posvetujte s svojim zdravnikom:  bolečine v prsih ali trdovraten in hud kašelj; neredno ali hitro bitje srca; težko dihanje, težava ostati buden, odrevenelost, mravljinci ali bolečina v dlaneh ali stopalih; epileptični napadi (konvulzije); težave z vidom, mišljenjem ali zbranostjo; spremenjeno duševno stanje; samomorilne misli ali poskus samomora, spremenjeno obnašanje ali agresivno obnašanje (včasih odkrito proti drugim), halucinacije; močne želodčne bolečine; črno ali smolnato blato; kri v blatu in seču, huda krvavitev iz nosu; voskasta bledica, visoka raven sladkorja v krvi, zvišana telesna temperatura ali mrzlica, ki nastopi po nekaj tednih zdravljenja, bolečina v spodnjem delu hrbta ali ob strani, težave z uriniranjem, težave z očmi ali vidom ali sluhom, izguba sluha, huda ali boleča pordelost ali ranice na koži ali sluznicah.
 359 At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors.
373 Na začetku zdravljenja z zdravilom IntronA boste lahko imeli gripi podobno reakcijo z zvišano telesno temperaturo, utrujenostjo, glavobolom, mišičnimi bolečinami, bolečinami v sklepih in mrzlico ali tresenjem.
Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients): thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, problem with your tear ducts, conjunctivitis (“pink eye”), agitation, sleepiness, sleepwalking, problem with behaviour, nervousness, stuffy or runny nose, sneezing, rapid breathing, pale or reddened skin, bruising, fingers and toes very sensitive to cold, problem with skin or nails, psoriasis (new or worsened), increased sweating, increased need to pass urine, fine shaking movements, decreased sensitivity to touch, arthritis.
Pogosto opisani neželeni učinki (pri najmanj 1 na vsakih 100 bolnikov, vendar manj kot 1 na vsakih 10 bolnikov): žeja, dehidracija, zvišan krvni tlak, migrene, otekle bezgavke, pordelost, težave z menstruacijo, zmanjšana spolna sla, vaginalne težave, bolečine v dojkah, bolečine v modih, težave z žlezo ščitnico, pordele dlesni, suha usta, pordela ali vneta usta ali jezik, zobobol ali zobne bolezni, herpes simpleks (vročinske razjede), sprememba okusa, želodčne težave, dispepsija (zgaga), zaprtje, povečanje jeter (jetrne težave, včasih hude), vodeno blato, močenje postelje pri otrocih, vnetje sinusov, bronhitis, očesne bolečine, težave s solznimi kanalčki, konjunktivitis (“ rdeče oko ”), vznemirjenost, zaspanost, hoja v spanju, vedenjske težave, živčnost, zamašen nos ali izcedek iz nosa, kihanje, hitro dihanje, bleda ali pordela koža, podplutbe, velika občutljivost prstov na rokah in nogah na mraz, težave s kožo ali nohti, psoriaza (novonastala ali poslabšanje obstoječe), povečano potenje, večja potreba po odvajanju urina, drobni tresoči gibi, zmanjšana občutljivost za dotik, artritis.
Uncommonly reported side effects (at least 1 in every 1000 patients, but less than 1 in every 100 patients): bacterial infection and feeling of pins and needles.
Občasno opisani neželeni učinki (pri najmanj 1 na vsakih 1. 000 bolnikov, vendar manj kot 1 na vsakih 100 bolnikov): bakterijske okužbe, pojav parastezij.
Additionally, Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord), thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement) have been reported with IntronA use.
374 Poleg tega so pri uporabi zdravila IntronA poročali tudi o pojavu sindroma Vogt- Koyanagi- Harada (avtoimunska vnetna bolezen, ki prizadene oči, kožo in ušesne membrane ter ovojnice možgan in hrbtenjače), misli kako ogroziti življenje drugih, manije (čezmerno ali nesmiselno navdušenje), bipolarne motnje (motnja razpoloženja, za katero je značilno izmenjevanje obdobij žalostnega razpoloženja z obdobji navdušenosti).
 360 Other side effects not listed above may also occur in some patients.
Pri nekaterih bolnikih se lahko pojavijo tudi drugi neželeni učinki, ki niso navedeni zgoraj.
For short term travelling, the non -reconstituted product can be kept out of the refrigerator at or below 25°C for a period up to four weeks before use.
Za kratkotrajen prevoz lahko nerekonstituirano zdravilo shranjujete zunaj hladilnika pri temperaturi do vključno 25°C, do 4 tedne pred uporabo.
- The active substance is recombinant interferon alfa-2b, 3 million IU/ml.
- Zdravilna učinkovina je rekombinantni interferon alfa- 2b, 3 milijoni i. e. / ml.
IntronA is available in two different pack sizes:
IntronA je na voljo v različnih velikostih pakiranja:
- Pack of 1 vial of powder for solution for injection or infusion, 1 ampoule of water for injections,
1 viala s praškom za raztopino za injiciranje ali infundiranje, 1 ampula vode za
1 injection syringe, 2 injection needles and 1 cleansing swab
injiciranje, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon
- Pack of 6 vials of powder for solution for injection or infusion and 6 ampoules of water for
6 vial s praškom za raztopino za injiciranje ali infundiranje in 6 ampul vode za
injections Not all pack sizes may be marketed.
injiciranje Na trgu ni vseh navedenih pakiranj.
Marketing Authorisation Holder:
375 Imetnik dovoljenja za promet z zdravilom:
Ireland Shire Park Welwyn Garden City Hertfordshire AL7 1TW Tel: +44 -(0)1 707 363 636
376 Slovenija Ireland Dunajska 22 Shire Park SI- 1000 Ljubljana Welwyn Garden City Tel: + 386 01 3001070 Hertfordshire AL7 1TW Tel: +44 - (0) 1 707 363 636
 363 HOW TO SELF INJECT INTRONA
377 KAKO SI LAHKO SAMI INJICIRATE ZDRAVILO INTRONA
Be sure the solution is at room temperature up to 25°C.
Raztopina mora biti pri sobni temperaturi do 25 C.
 364 Injecting the solution Select the injection site.
Injiciranje raztopine Izberite si mesto, kamor boste injicirali zdravilo.
The best sites for injection are tissues with a layer of fat between skin and muscle: thigh, outer surface of the upper arm (you may need the assistance of another person to use this site), abdomen (except the navel or waistline).
Najboljša mesta za injiciranje so tkiva s plastjo maščevja med kožo in mišicami: stegno, zunanja površina nadlahti (tu boste morda potrebovali pomoč 378 druge osebe), trebuh (razen popka ali pasu).
INFORMATION FOR THE USER
379 NAVODILO ZA UPORABO
IntronA 5 million IU/ml powder and solvent for solution for injection or infusion Interferon alfa-2b
IntronA 5 milijonov i. e. / ml prašek in vehikel za raztopino za injiciranje ali infundiranje interferon alfa- 2b
 367 Using IntronA with food and drink While being treated with IntronA, your doctor may want you to drink extra fluids to help prevent low blood pressure.
381 Uporaba zdravila IntronA skupaj s hrano in pijačo Medtem, ko prejemate zdravilo IntronA vam bo vaš zdravnik lahko naročil, naj pijete več tekočine, da bi preprečili nizek krvni tlak.
 368 If you are injecting IntronA yourself, please be sure that the dose that has been prescribed for you is clearly provided with the package of medicine you receive.
382 Če si zdravilo IntronA injicirate sami, pazite, da bo predpisani odmerek jasno napisan na pakiranju zdravila, ki ga jemljete.
 369 Use IntronA exactly as prescribed by your doctor.
383 Pri uporabi zdravila IntronA natančno upoštevajte zdravnikova navodila.
 370 At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors.
384 Na začetku zdravljenja z zdravilom IntronA boste lahko imeli gripi podobno reakcijo z zvišano telesno temperaturo, utrujenostjo, glavobolom, mišičnimi bolečinami, bolečinami v sklepih in mrzlico ali tresenjem.
Additionally, Vogt-Koyanagi-Harada syndrome (an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord), thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement) have been reported with IntronA use.
385 Poleg tega so pri uporabi zdravila IntronA poročali tudi o pojavu sindroma Vogt- Koyanagi- Harada (avtoimunska vnetna bolezen, ki prizadene oči, kožo in ušesne membrane ter ovojnice možgan in hrbtenjače), misli kako ogroziti življenje drugih, manije (čezmerno ali nesmiselno navdušenje), bipolarne motnje (motnja razpoloženja, za katero je značilno izmenjevanje obdobij žalostnega razpoloženja z obdobji navdušenosti).
 371 Other side effects not listed above may also occur in some patients.
Pri nekaterih bolnikih se lahko pojavijo tudi drugi neželeni učinki, ki niso navedeni zgoraj.
- The active substance is recombinant interferon alfa-2b, 5 million IU/ml.
- Zdravilna učinkovina je rekombinantni interferon alfa- 2b, 5 milijonov i. e. / ml.
IntronA is presented as a powder and solvent for solution for injection or infusion.
IntronA je navoljo kot prašek in vehikel za raztopino za injiciranje ali infundiranje.
The white to cream coloured powder is contained in a 2 ml glass vial and the clear and colourless solvent is presented in a 2 ml glass ampoule
Prašek bele do krem barve je v 2 ml stekleni viali, bister in brezbarven vehikel pa v 2 ml stekleni ampuli.
IntronA is available in two different pack sizes:
IntronA je na voljo v dved različnih velikostih pakiranja:
Marketing Authorisation Holder:
386 Imetnik dovoljenja za promet z zdravilom:
Ireland Shire Park Welwyn Garden City Hertfordshire AL7 1TW Tel: +44 -(0)1 707 363 636
387 Slovenija Ireland Dunajska 22 Shire Park SI- 1000 Ljubljana Welwyn Garden City Tel: + 386 01 3001070 Hertfordshire AL7 1TW Tel: +44 - (0) 1 707 363 636